Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...
F. Kahles, B. Kurt, K. Schneider et al.· European Heart Journal· 0 citations
High-sensitivity C-reactive protein (hsCRP) is the guideline-recommended biomarker for assessment of residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD). Clinical adoption remains limited, especially in individuals without established ASCVD. This study used longitudinal measurements to ev...
B. Kurt, M. Reugels, K. Schneider et al.· European Heart Journal· 0 citations
Traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) fail to fully reflect the residual risk, driven by chronic low-grade inflammation, observed in many. Generally, high-sensitivity C-reactive protein (hsCRP) concentrations remain stable, but some individuals may experience increases. More...
F. Kahles, M. Reugels, K. Schneider et al.· European Heart Journal· 0 citations
BACKGROUND: In SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), among 17 604 patients with known atherosclerotic cardiovascular disease and overweight or obesity, but not diabetes, randomization to the glucagon-like peptide-1 receptor agonist semaglutide significantly red...
Jorge Plutzky, P. Bogdański, H. Colhoun et al.· Circulation· 1 citation
Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...
Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al.· Nature Reviews Nephrology· 1 citation
Efforts to use inflammatory biomarkers to more precisely identify patients who may benefit may further improve the benefit‐to‐risk profile of emerging therapies.
M. Spindler, P. Libby, P. Ridker· Immunological Reviews· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.